# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yesc...
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver a...
HC Wainwright & Co. analyst Ed Arce reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and maintains $32.5 pri...
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate o...
Leerink Partners analyst Thomas Smith downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform and an...
LifeSci Capital analyst Cory Jubinville downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.
Piper Sandler analyst Yasmeen Rahimi downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and lowers the...